logo

For the Inventor, By the Inventor

Richmond, CA, United States of America

Sangamo Therapeutics, Inc.

USPTO Granted Patents = 154

% Expired Patents = 14.3



Forward Citations = 558

Loading Chart...
Loading Chart...

122 inventors (with patents filed for the assignee):

goldMedal Jeffrey C Miller (51 out of 88 patents)

silverMedal Edward J Rebar (47 out of 91 patents)

bronzeMedal Fyodor Urnov (33 out of 80 patents)

4.  David Paschon (32 out of 51 patents)

5.  Michael C Holmes (30 out of 64 patents)

6.  Philip D Gregory (24 out of 62 patents)

7.  Lei Zhang (24 out of 44 patents)

8.  H Steve Zhang (19 out of 29 patents)

9.  Andreas Reik (17 out of 23 patents)

10.  Dmitry Y Guschin (15 out of 21 patents)

11.  Anthony Conway (15 out of 16 patents)

12.  Gregory J Cost (15 out of 25 patents)

13.  Jianbin Wang (12 out of 18 patents)

14.  Gary K Lee (11 out of 16 patents)

15.  Steven Robert Webb (10 out of 43 patents)


Core Competencies:
Gene Editing
Transgene Expression
Engineered Nucleases
AAV Engineering
Cell Targeting
Huntington's Disease
Lysosomal Storage Diseases
Cytokine Modulation
CRISPR
Zinc Finger Proteins
Genome Engineering
HLA Locus Modification

154 patents:

1. 12758654 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY DISEASE (2026-10-13),
2. 12747273 - HTT repressors comprising a zinc-finger protein transcription factor. (2026-09-29),
3. 12653861 - METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE (2026-06-16),
4. 12630839 - COMPOSITIONS FOR THE TREATMENT OF FABRY DISEASE (2026-05-19),
5. 12565685 - ENGINEERING AAV (2026-03-03),
6. 12551575 - HTT REPRESSORS AND USES THEREOF (2026-02-17),
7. 12516098 - CHIMERIC ANTIGEN RECEPTOR MEDIATED CELL TARGETING (2026-01-06),
8. 12509703 - Controlled Transgene Expression in Regulatory T Cells (2025-12-30),
9. 12497632 - IMPROVED CLINICAL PARAMETERS BY EXPRESSION OF FACTOR VIII (2025-12-16),
10. 12318427 - Methods and compositions for modulation of tau proteins (2025-06-03),
11. 12139517 - Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof (2024-11-12),
12. 12043650 - Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene (2024-07-23),
13. 11981967 - Engineering AAV (2024-05-14),
14. 11920169 - Compositions for linking DNA-binding domains and cleavage domains (2024-03-05),
15. 11898158 - Methods and compositions for the treatment of lysosomal storage diseases (2024-02-13),
Company Overview
Sangamo Therapeutics, Inc. is a biotechnology company based in Richmond, California, specializing in gene editing technologies. The company focuses on developing innovative therapies utilizing engineered nucleases and AAV engineering to address genetic disorders, including Huntington's disease and lysosomal storage diseases. Sangamo's expertise extends to transgene expression and cell targeting, positioning it at the forefront of advancements in genetic medicine and cytokine modulation, aiming to transform treatment paradigms for various diseases.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Sangamo Therapeutics, Inc. USPTO Patent Assignee Logo
154 Patents

#2 in Richmond, CA

#567 in California

#2,574 in US

#5,322 in the World

Richmond, CA (US)
Richmond, CA, United States of America

Sangamo Therapeutics, Inc.

Forward Citations = 558

122 inventors:

goldMedal Jeffrey C Miller (51 out of 88 patents)

silverMedal Edward J Rebar (47 out of 91 patents)

bronzeMedal Fyodor Urnov (33 out of 80 patents)

4.  David Paschon (32 out of 51 patents)

5.  Michael C Holmes (30 out of 64 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sangamo Therapeutics, Inc.. Retrieved from https://idiyas.com/company/sangamo-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…